Avicanna Inc. (TSX: AVCN) (OTCQX: AVCNF) posted fourth-quarter revenue of $6.6 million for the period ending Dec. 31, 2024, wrapping up a year of some stability in the Canadian biopharmaceutical company’s commercial ventures. Still, it posted a fourth-quarter net loss of $440,094, a significant improvement versus the $2.4 million loss …